About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01223911

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0...

Lead sponsor: Novo Nordisk A/S•16 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novo Nordisk A/S

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•CZ: Age between 18 and 65 years (both inclusive)
•A diagnosis of rheumatoid arthritis of at least three months before entry in trial
•Active rheumatoid arthritis (RA)
•Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration

Exclusion Criteria

•Known or suspected allergy to trial product or related products
•Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)

Related studies

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

NCT07171983 · Rheumatoid Arthritis

CoreSys Monitoring for Intraoperative Stress Management in Abdominal Hysterectomy

NCT07571473 · Surgical Stress Response, Inflammation, and more

Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation

NCT07011394 · Diagnosis, Inflammation, and more

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction

NCT05190978 · Breast Cancer, Breast Implant; Complications, Infection or Inflammation

RECRUITINGPhase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 9, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment34

Start dateJan 2011

Last updatedFeb 9, 2017

Condition

Inflammation Rheumatoid Arthritis

Locations shown

Novo Nordisk Investigational Site

Prague

Novo Nordisk Investigational Site

Frederiksberg

Novo Nordisk Investigational Site

Silkeborg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions